C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s = 25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
Ametantrone (AM), a synthetic 9,10-anthracenedione bearing two ethylamino residues at positions 1 and 4, is the second anthracene derivative to enter clinical trials.
N-Trifluoroacetyladriamycin is a metabolite of Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar). Valrubicin is a chemotherapy drug utilized to treat bladder cancer. Valrubicin is the anthracycline doxorubicin analog and is administ